Pasko M T, Beam T R
Infectious Diseases Section, Buffalo VA Medical Center, NY 14215.
Am J Public Health. 1990 May;80(5):590-3. doi: 10.2105/ajph.80.5.590.
Health care personnel who received the hepatitis B vaccine (Heptavax-BR, MSD) were followed for persistence of hepatitis B surface antibody (anti-HBs). Response occurred in 135/146 (92.5 percent) vaccinees. Loss of anti-HBs (less than 72 RIA units; 10 S/N) occurred in 35.9 percent during the 36-month surveillance. Stepwise discriminant analysis found age and magnitude of initial antibody level, but not weight-height index, to be predictive of antibody loss over the 36 months. Twenty-four of 27 employees (88.9 percent) who lost anti-HBs responded to a fourth vaccine dose. In contrast, three of eight initial non-responders (37.5 percent) developed antibody after a fourth vaccine dose.
对接种了乙肝疫苗(Heptavax-BR,默克公司生产)的医护人员进行随访,观察乙肝表面抗体(抗-HBs)的持续情况。146名接种者中有135人(92.5%)出现反应。在36个月的监测期内,35.9%的人抗-HBs消失(低于72放射免疫分析单位;10 S/N)。逐步判别分析发现,年龄和初始抗体水平的高低,而非体重身高指数,可预测36个月内抗体的消失情况。27名抗-HBs消失的员工中有24人(88.9%)对第四剂疫苗有反应。相比之下,8名初始无反应者中有3人(37.5%)在接种第四剂疫苗后产生了抗体。